301 related articles for article (PubMed ID: 31300530)
1. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
2. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
[TBL] [Abstract][Full Text] [Related]
3. Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.
Gupta R; Strbenac D; Satgunaseelan L; Cheung VK; Narayanappa H; Ashford B; Mitchell J; Thind A; Palme CE; Ch'ng S; Low TH; Wykes J; Willet CE; Chew T; Yang J; Ranson M; Clark JR
Mod Pathol; 2023 Aug; 36(8):100190. PubMed ID: 37080394
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
[TBL] [Abstract][Full Text] [Related]
7. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
Galot R; Le Tourneau C; Guigay J; Licitra L; Tinhofer I; Kong A; Caballero C; Fortpied C; Bogaerts J; Govaerts AS; Staelens D; Raveloarivahy T; Rodegher L; Laes JF; Saada-Bouzid E; Machiels JP
Ann Oncol; 2018 Dec; 29(12):2313-2327. PubMed ID: 30307465
[TBL] [Abstract][Full Text] [Related]
8. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
9. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
10. The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.
Harwood CA; Proby CM; Inman GJ; Leigh IM
Acta Derm Venereol; 2016 Jan; 96(1):3-16. PubMed ID: 26084328
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system.
Nallaiah S; Lee VMY; Brasch HD; de Jongh J; Schaijik BV; Marsh R; Tan ST; Itinteang T
J Plast Reconstr Aesthet Surg; 2019 Sep; 72(9):1484-1493. PubMed ID: 30528285
[TBL] [Abstract][Full Text] [Related]
13. Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.
Giefing M; Wierzbicka M; Szyfter K; Brenner JC; Braakhuis BJ; Brakenhoff RH; Bradford CR; Sorensen JA; Rinaldo A; Rodrigo JP; Takes RP; Ferlito A
Eur J Cancer; 2016 Mar; 55():147-57. PubMed ID: 26851381
[TBL] [Abstract][Full Text] [Related]
14. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.
Donnadieu J; Lachaier E; Peria M; Saidak Z; Dakpe S; Ikoli JF; Chauffert B; Page C; Galmiche A
BMC Cancer; 2016 Apr; 16():273. PubMed ID: 27085492
[TBL] [Abstract][Full Text] [Related]
15. Cell death in head and neck cancer pathogenesis and treatment.
Raudenská M; Balvan J; Masařík M
Cell Death Dis; 2021 Feb; 12(2):192. PubMed ID: 33602906
[TBL] [Abstract][Full Text] [Related]
16. CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?
Rudhart SA; Schultz JD; Gehrt F; Pavel FL; Birk R; Hoch M; Stuck BA; Hoch S
Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3467-3475. PubMed ID: 31482332
[TBL] [Abstract][Full Text] [Related]
17. A critical analysis of the 8th edition TNM staging for head and neck cutaneous squamous cell carcinoma with lymph node metastases and comparison to N1S3 stage and ITEM risk score: A multicenter study.
Ebrahimi A; Luk PP; Low H; McDowell L; Magarey MJR; Smith PN; Perriman DM; Veness M; Gupta R; Clark JR
J Surg Oncol; 2021 Jun; 123(7):1531-1539. PubMed ID: 33721339
[TBL] [Abstract][Full Text] [Related]
18. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
[TBL] [Abstract][Full Text] [Related]
19. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt T; Magnes T; Hufnagl C; Thorner AR; Ducar M; Neureiter D; Tränkenschuh W; Klieser E; Gaggl A; Rösch S; Rasp G; Hartmann TN; Pleyer L; Rinnerthaler G; Weiss L; Greil R; Egle A
Eur J Cancer; 2018 Apr; 93():69-78. PubMed ID: 29477794
[TBL] [Abstract][Full Text] [Related]
20. Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion.
Sasaki E; Nishikawa D; Hanai N; Hasegawa Y; Yatabe Y
Histopathology; 2018 Dec; 73(6):953-962. PubMed ID: 30117182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
